RSS feed (help and list of feeds)
Consultation
We ask for feedback on proposals through public consultation, and take into account all consultation responses we receive before making our decisions. PHARMAC has published guidance for consumers on getting involved in our decisions, and this includes responses to consultation. You can download the document here (8 pages, 100 KB).
We welcome feedback from pharmaceutical suppliers, health professionals, health interest groups and the general public. This page includes consultations that are currently underway.
You can respond to consultation by writing to the address at the bottom of the consultation letter.
Rapid response
If you would like to make a rapid response to any of our consultations, click 
here. Remember to indicate which consultation proposal your comments relate to.
Search for previous consultation documents
- CAC Draft Terms of Reference 2010 (25 pages, 183 KB) 05 Mar 2010
- Proposal to fund donepezil. Closes 4pm, Friday 19 March 2010 (2 pages, 57 KB) 05 Mar 2010
- Rationale for Draft CAC Terms of Reference (12 pages, 155 KB) 05 Mar 2010
- Proposal to widen access to fentanyl transdermal patches. Closes Thursday 18 March 2010 (3 pages, 152 KB) 04 Mar 2010
- Proposal to amend Growth Hormone access criteria. Closes Friday 12 March 2010 (2 pages, 150 KB) 24 Feb 2010
- Proposal to widen access to gemcitabine hydrochloride and vinorelbine. Closed (4 pages, 172 KB) 19 Feb 2010
- Proposal to fund lignocaine urethral syringes. Closed (1 page, 103 KB) 17 Feb 2010
- Proposal to fund bisacodyl suppositories (Dulcolax). Closed (1 page, 105 KB) 15 Feb 2010
- Proposal to reference price risperidone. Closed (3 pages, 154 KB) 15 Feb 2010
- Proposal relating to provisional agreement with Allergan Australia Pty Ltd for various products. Closed (3 pages, 160 KB) 12 Feb 2010
- Proposal to fund ambrisentan (Volibris). Closed (2 pages, 163 KB) 29 Jan 2010
- Proposal to fund donepezil and decline memantine applications. Closed (3 pages, 55 KB) 27 Jan 2010
- Consultation on altering subsidies for Special Foods. Closes Friday 19 March 2010 (38 pages, 610 KB) 19 Jan 2010
- Proposal to amend claiming for Cost Brand Source prescriptions. Closed (1 page, 102 KB) 11 Jan 2010
- Proposal for funding a multivitamin. Closed (2 pages, 53 KB) 05 Jan 2010
- Consultation to widen access to ursodeoxycholic acid for cholestasis of pregnancy. Closed (2 pages, 109 KB) 17 Dec 2009
- Consultation relating to listing of flecainide acetate. Closed (1 page, 109 KB) 15 Dec 2009
- Consultation to change dispensing rules for pregnancy tests. Closed (1 page, 48 KB) 10 Dec 2009
- Consultation to reference price certain glaucoma treatments. Closed. (2 pages, 149 KB) 10 Dec 2009
- Proposal to amend alendronate Special Authority. Closed (3 pages, 98 KB) 03 Dec 2009
Page updated on 12 Mar 2010
Linked documents
Having Your Say in our Decisions (8 pages, 100 KB)
Pharmaceutical Management Agency Having your say in our decisions PHARMAC’s decision-making PHARMAC is the Government agency that decides which medicines are funded for New Zealanders. We welcome input from people into our decision-making processes. There are a number of ways…
CAC Draft Terms of Reference 2010 (25 pages, 183 KB)
1 CONTENTS 1 2 3 Establishment…..4 1.1 2.1 3.1 3.2 3.3 4 5 6 7 8 4.1 The CAC ….4 Purpose of the CAC …..4 Relationship with PHARMAC…5 Relationship with PHARMAC staff ….5 Indemnity for Members …6 Appointment of the…
Proposal to fund donepezil. Closes 4pm, Friday 19 March 2010 (2 pages, 57 KB)
5 March 2010 Updated proposal to fund donepezil hydrochloride PHARMAC recently sought feedback on a proposal to fund donepezil hydrochloride for the treatment of Alzheimer’s disease, subject to Special Authority restrictions. Following consideration of responses to consultation on that proposal,…
Rationale for Draft CAC Terms of Reference (12 pages, 155 KB)
1 Introduction PHARMAC is reviewing the Terms of Reference (Terms of Reference) of our Consumer Advisory Committee (CAC). The review was required in Actioning Medicines New Zealand, the action plan accompanying the Government’s Medicines Strategy, Medicines New Zealand, and provides…
Proposal to widen access to fentanyl transdermal patches. Closes Thursday 18 March 2010 (3 pages, 152 KB)
4 March 2010 Proposal to widen access to fentanyl transdermal patches under a sole supply arrangement PHARMAC is seeking feedback on a proposal to list a new brand of fentanyl transdermal patches, Duropatch, as soon as possible (following Medsafe registration)…
Proposal to amend Growth Hormone access criteria. Closes Friday 12 March 2010 (2 pages, 150 KB)
24 February 2010 Proposal to Amend Growth Hormone Access Criteria PHARMAC is seeking feedback on a proposal to make several amendments to the Growth Hormone Access Criteria. In summary, this proposal would result in: § a revision of the cut-off…
Proposal to widen access to gemcitabine hydrochloride and vinorelbine. Closed (4 pages, 172 KB)
19 February 2010 Proposal to widen access to gemcitabine hydrochloride and vinorelbine PHARMAC is seeking feedback on a proposal to widen funded access to gemcitabine hydrochloride. In summary, the proposal involves: § § Widening access to subsidised gemcitabine and vinorelbine…
Proposal to fund lignocaine urethral syringes. Closed (1 page, 103 KB)
17 February 2010 Proposal to fund lignocaine urethral syringes PHARMAC is seeking feedback on a proposal to list lignocaine gel 2% (10 ml urethral syringe) in Section B and in Part II of Section H of the Pharmaceutical Schedule from…
Proposal to fund bisacodyl suppositories (Dulcolax). Closed (1 page, 105 KB)
15 February 2010 Proposal to fund bisacodyl suppositories (Dulcolax) PHARMAC is seeking feedback on a proposal to fund a new brand of bisacodyl 10 mg suppositories (Dulcolax) and fully fund the 5 mg strength (Dulcolax) on the Pharmaceutical Schedule. This…
Proposal to reference price risperidone. Closed (3 pages, 154 KB)
15 February 2010 Proposal to apply reference pricing across different brands of risperidone PHARMAC is seeking feedback on a proposal to apply reference pricing across different brands of risperidone from 1 June 2010, where such reference pricing is possible in…
Proposal relating to provisional agreement with Allergan Australia Pty Ltd for various products. Closed (3 pages, 160 KB)
12 February 2010 Proposal relating to bimatoprost, brimonidine tartrate with timolol maleate and prednisolone actate PHARMAC is seeking feedback on a proposal relating to a provisional agreement with Allergan Australia Pty Ltd for a number of products. In summary, this…
Proposal to fund ambrisentan (Volibris). Closed (2 pages, 163 KB)
29 January 2010 Proposal to fund ambrisentan (Volibris) for the treatment of pulmonary arterial hypertension PHARMAC is seeking feedback on a proposal to list ambrisentan (Volibris) in the Pharmaceutical Schedule for the treatment of pulmonary arterial hypertension. In summary, the…
Proposal to fund donepezil and decline memantine applications. Closed (3 pages, 55 KB)
27 January 2010 Proposal to fund donepezil hydrochloride and to decline funding for memantine hydrochloride PHARMAC is seeking feedback on a proposal to fund donepezil hydrochloride for the treatment of Alzheimer’s disease, subject to Special Authority restrictions (outlined on page…
Consultation on altering subsidies for Special Foods. Closes Friday 19 March 2010 (38 pages, 610 KB)
January 2010 Special Foods Consultation Document Proposals regarding the funding and access arrangements for a number of Special Foods Funding and access for a number of Special Foods Summary Foods are subsidised in the Pharmaceutical Schedule for a wide range…
Proposal to amend claiming for Cost Brand Source prescriptions. Closed (1 page, 102 KB)
11 January 2010 Proposal to amend claiming for Cost Brand Source prescriptions PHARMAC is seeking feedback on a proposal to amend the way Cost Brand Source (CBS) prescriptions are annotated when claimed. PHARMAC proposes to amend the way pharmacists annotate…
Proposal for funding a multivitamin. Closed (2 pages, 53 KB)
5 January 2010 Proposal for funding a new multivitamin PHARMAC is seeking feedback on a proposal to fund a multivitamin containing the fatsoluble vitamins A, D, E and K for patients with cystic fibrosis with pancreatic insufficiency and infants or…
Consultation to widen access to ursodeoxycholic acid for cholestasis of pregnancy. Closed (2 pages, 109 KB)
17 December 2009 Proposal to widen access to ursodeoxycholic acid for cholestasis of pregnancy PHARMAC is seeking feedback on a proposal to amend the current ursodeoxycholic acid Special Authority restriction to widen access to patients with cholestasis of pregnancy. Ursodeoxycholic…
Consultation relating to listing of flecainide acetate. Closed (1 page, 109 KB)
15 December 2009 Proposal relating to the listing of flecainide acetate PHARMAC is seeking feedback on a provisional agreement with Douglas Pharmaceuticals Limited relating to the listing of flecainide acetate (Tambocor and Tambocor CR) in the Pharmaceutical Schedule. Flecainide acetate…
Consultation to change dispensing rules for pregnancy tests. Closed (1 page, 48 KB)
10 December 2009 Proposal to amend the dispensing rules for pregnancy tests PHARMAC is seeking feedback on a proposal to change the way in which subsidised pregnancy tests are made available to clinicians. PHARMAC proposes to amend the restriction applying…
Consultation to reference price certain glaucoma treatments. Closed. (2 pages, 149 KB)
10 December 2009 Consultation on a proposal to reference price certain glaucoma treatments Following the listing of the Hysite brand of latanoprost (as a result of the 2008/09 Multiproduct annual tender), PHARMAC now proposes to apply reference pricing to the…
Proposal to amend alendronate Special Authority. Closed (3 pages, 98 KB)
3 December 2009 Proposal to amend the alendronate Special Authority Proposal summary PHARMAC is seeking feedback on a proposal to amend the Alendronate for Osteoporosis Special Authority applying to alendronate +/- cholecalciferol (Fosamax and Fosamax Plus). The proposed amendment would…
